Search

Your search keyword '"Frau, Jessica"' showing total 434 results
Start Over Author "Frau, Jessica"
434 results on '"Frau, Jessica"'

2. ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis

Author

Maida, Elisabetta, Moccia, Marcello, Palladino, Raffaele, Borriello, Giovanna, Affinito, Giuseppina, Clerico, Marinella, Repice, Anna Maria, Di Sapio, Alessia, Iodice, Rosa, Spiezia, Antonio Luca, Sparaco, Maddalena, Miele, Giuseppina, Bile, Floriana, Scandurra, Cristiano, Ferraro, Diana, Stromillo, Maria Laura, Docimo, Renato, De Martino, Antonio, Mancinelli, Luca, Abbadessa, Gianmarco, Smolik, Krzysztof, Lorusso, Lorenzo, Leone, Maurizio, Leveraro, Elisa, Lauro, Francesca, Trojsi, Francesca, Streito, Lidia Mislin, Gabriele, Francesca, Marinelli, Fabiana, Ianniello, Antonio, De Santis, Federica, Foschi, Matteo, De Stefano, Nicola, Morra, Vincenzo Brescia, Bisecco, Alvino, Coghe, Giancarlo, Cocco, Eleonora, Romoli, Michele, Corea, Francesco, Leocani, Letizia, Frau, Jessica, Sacco, Simona, Inglese, Matilde, Carotenuto, Antonio, Lanzillo, Roberta, Padovani, Alessandro, Triassi, Maria, Bonavita, Simona, and Lavorgna, Luigi

Published
2024
Full Text
View/download PDF

4. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Author

Signoriello, Elisabetta, Signori, Alessio, Lus, Giacomo, Romano, Giuseppe, Marfia, Girolama Alessandra, Landi, Doriana, Napoli, Francesca, D' Amico, Emanuele, Zanghí, Aurora, Di Filippo, Paola Sofia, Caliendo, Daniele, Carotenuto, Antonio, Spiezia, Antonio Luca, Fantozzi, Roberta, Centonze, Diego, Lucchini, Matteo, Mirabella, Massimiliano, Cocco, Eleonora, Frau, Jessica, Maniscalco, Giorgia Teresa, Di Battista, Maria Elena, Foschi, Matteo, Surcinelli, Andrea, Bonavita, Simona, Abbadessa, Gianmarco, Pasquali, Livia, Di Gregorio, Maria, Ferrò, Maria Teresa, Sormani, Maria Pia, and Schiavetti, Irene

Published
2024
Full Text
View/download PDF

7. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

Author

Sottini, Alessandra, Quaresima, Virginia, Barbaro, Mosè, Moiola, Lucia, Filippi, Massimo, Malentacchi, Maria, Capobianco, Marco, Puthenparampil, Marco, Gallo, Paolo, Cocco, Eleonora, Frau, Jessica, Zaffaroni, Mauro, Guaschino, Clara, Stampatori, Chiara, Mancinelli, Chiara, Brambilla, Laura, Clerici, Valentina Torri, Vianello, Marika, Vitetta, Francesca, Ferraro, Diana, Rosettani, Pamela, Danni, Maura Chiara, Conti, Marta, Grimoldi, Maria, Capra, Ruggero, and Imberti, Luisa

Published
2023
Full Text
View/download PDF

10. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.

Author

Lapucci, Caterina, Frau, Jessica, Cocco, Eleonora, Coghe, Giancarlo, Petracca, Maria, Lanzillo, Roberta, Brescia Morra, Vincenzo, Nicoletti, Carolina Gabri, Landi, Doriana, Marfia, Girolama, Vercellino, Marco, Cavalla, Paola, Bianco, Assunta, Mirabella, Massimiliano, Torri Clerici, Valentina, Tomas, Eugenia, Ferrò, Maria Teresa, Grossi, Paola, Nozzolillo, Agostino, and Moiola, Lucia

Subjects
*MAGNETIC resonance imaging, *IMMUNOGLOBULIN M, *THERAPEUTICS, *MULTIPLE sclerosis, *ALEMTUZUMAB
Abstract

Background: The reason why some multiple sclerosis (MS) patients show disease activity after alemtuzumab (ALM) is still unclear, but ocrelizumab (OCR) could represent an interesting sequential therapeutic approach. Objectives: To investigate safety and efficacy of OCR in MS patients with disease activity after two ALM courses. Methods: Observational retrospective multi-centers Italian cohort study. Results: Seventy-two subjects were included. Mean follow-up (FU) was 2.4 (±1) years. Forty-five patients (62.5%) experienced at least one adverse event (AE), with infections accounting for 96.7% of cases. A reduction in total lymphocytes was observed between OCR start and 6 months FU, driven by BCD19+ lymphocytes depletion (p < 0.001). Immunoglobulin M (IgM) levels decreased between OCR start and 6 months FU (p < 0.001). At 2-year FU, relapse, magnetic resonance imaging (MRI) activity and disability worsening-free survival were 92.1%, 90.8%, and 89.2%. The evidence of inflammatory activity between the two ALM courses was associated with higher risk of relapse, MRI activity, and NEDA-3 status loss in relapsing-remitting multiple sclerosis (RRMS; p = 0.02, p = 0.05, p = 0.01, respectively). Conclusions: OCR after two ALM courses seemed to be safe and effective. Early IgM hypogammaglobulinemia occurred in a high proportion of patients. The evidence of inflammatory activity between ALM courses seemed to increase the risk of MS re-activation on OCR treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination.

Author

Orrù, Valeria, Serra, Valentina, Marongiu, Michele, Lai, Sandra, Lodde, Valeria, Zoledziewska, Magdalena, Steri, Maristella, Loizedda, Annalisa, Lobina, Monia, Piras, Maria Grazia, Virdis, Francesca, Delogu, Giuseppe, Marini, Maria Giuseppina, Mingoia, Maura, Floris, Matteo, Masala, Marco, Castelli, M. Paola, Mostallino, Rafaela, Frau, Jessica, and Lorefice, Lorena

Subjects
COVID-19 vaccines, VACCINE effectiveness, BOOSTER vaccines, COVID-19 pandemic, DIMETHYL fumarate, NATALIZUMAB, FINGOLIMOD
Abstract

Introduction: Disease-modifying therapies (DMTs) have been shown to improve disease outcomes in multiple sclerosis (MS) patients. They may also impair the immune response to vaccines, including the SARS-CoV-2 vaccine. However, available data on both the intrinsic immune effects of DMTs and their influence on cellular response to the SARS-CoV-2 vaccine are still incomplete. Methods: Here, we evaluated the immune cell effects of 3 DMTs on the response to mRNA SARS-CoV-2 vaccination by comparing MS patients treated with one specific therapy (fingolimod, dimethyl fumarate, or natalizumab) with both healthy controls and untreated patients. We profiled 23 B-cell traits, 57 T-cell traits, and 10 cytokines, both at basal level and after stimulation with a pool of SARS-CoV-2 spike peptides, in 79 MS patients, treated with DMTs or untreated, and 32 healthy controls. Measurements were made before vaccination and at three time points after immunization. Results and Discussion: MS patients treated with fingolimod showed the strongest immune cell dysregulation characterized by a reduction in all measured lymphocyte cell classes; the patients also had increased immune cell activation at baseline, accompanied by reduced specific immune cell response to the SARS-CoV-2 vaccine. Also, anti-spike specific B cells progressively increased over the three time points after vaccination, even when antibodies measured from the same samples instead showed a decline. Our findings demonstrate that repeated booster vaccinations in MS patients are crucial to overcoming the immune cell impairment caused by DMTs and achieving an immune response to the SARS-CoV-2 vaccine comparable to that of healthy controls. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).

Author

Schiavetti, Irene, Signori, Alessio, Albanese, Angela, Frau, Jessica, Cocco, Eleonora, Lorefice, Lorena, di Lemme, Sonia, Fantozzi, Roberta, Centonze, Diego, Landi, Doriana, Marfia, Girolama, Signoriello, Elisabetta, Lus, Giacomo, Zecca, Chiara, Gobbi, Claudio, Iodice, Rosa, Malimpensa, Leonardo, Cordioli, Cinzia, Ferraro, Diana, and Ruscica, Francesca

Subjects
OLDER patients, DISEASE relapse, MULTIPLE sclerosis, CHRONIC hepatitis B
Abstract

Background and purpose: Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment needed in years 3 and 4. However, comprehensive evidence regarding patient outcomes beyond the initial 24 months of cladribine treatment is limited. Methods: This retrospective, multicenter study enrolled 204 patients with multiple sclerosis who had completed the 2‐year course of cladribine treatment. The primary outcomes were therapeutic choices and clinical disease activity assessed by annualized relapse rate after the 2‐year treatment course. Results: A total of 204 patients were enrolled; most patients (75.4%) did not initiate new treatments in the 12 months postcladribine. The study found a significant reduction in annualized relapse rate at the 12‐month follow‐up after cladribine completion compared to the year prior to starting therapy (0.07 ± 0.25 vs. 0.82 ± 0.80, p < 0.001). Furthermore, patients with relapses during cladribine treatment were more likely to start new therapies, whereas older patients were less likely. The safety profile of cladribine was favorable, with lymphopenia being the primary registered adverse event. Conclusions: This study provides insights into therapeutic choices and disease activity following cladribine treatment. It highlights cladribine's effectiveness in reducing relapse rates and disability progression, reaffirming its favorable safety profile. Real‐world data, aligned with previous reports, draw attention to ocrelizumab and natalizumab as common choices after cladribine. However, larger, prospective studies for validation and a more comprehensive understanding of cladribine's long‐term impact are necessary. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study

Author

Moccia, Marcello, Frau, Jessica, Carotenuto, Antonio, Butera, Calogera, Coghe, Giancarlo, Barbero, Pierangelo, Frontoni, Marco, Groppo, Elisabetta, Giovannelli, Morena, Del Carro, Ubaldo, Inglese, Cristina, Frasson, Emma, Castagna, Anna, Buccafusca, Maria, Latino, Pamela, Nascimbene, Caterina, Romano, Marcello, Liotti, Vitalma, Lanfranchi, Stefania, Rapisarda, Laura, Lori, Silvia, Esposito, Marcello, Maggi, Loredana, Petracca, Martina, Lo Fermo, Salvatore, Altavista, Maria Concetta, Bono, Francesco, Eleopra, Roberto, and Brescia Morra, Vincenzo

Published
2020
Full Text
View/download PDF

15. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

Author

Novi, Giovanni, Bovis, Francesca, Capobianco, Marco, Frau, Jessica, Mataluni, Giorgia, Curti, Erica, Zuliani, Luigi, Cavalla, Paola, Brambilla, Laura, Annovazzi, Pietro, Repice, Anna Maria, Lanzillo, Roberta, Esposito, Sabrina, Benedetti, Luana, Maietta, Ilaria, Sica, Francesco, Buttari, Fabio, Malucchi, Simona, Fenu, Giuseppe, Landi, Doriana, Bosa, Chiara, Realmuto, Sabrina, Malentacchi, Maria, Granella, Franco, Signori, Alessio, Bonavita, Simona, Uccelli, Antonio, and Sormani, Maria Pia

Published
2019
Full Text
View/download PDF

16. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Author

Sormani, Maria Pia, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Filippi, Massimo, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, De Rossi, Nicola, Brichetto, Giampaolo, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Zito, Antonio, Confalonieri, Paolo, Marfia, Girolama Alessandra, Perini, Paola, Inglese, Matilde, Trojano, Maria, Brescia Morra, Vincenzo, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario Alberto, Patti, Francesco, Salvetti, Marco, Abbadessa, Gianmarco, Aguglia, Umberto, Allegorico, Lia, Allegri Rossi, Beatrice Maria, Amato, Maria Pia, Annovazzi, Pietro, Antozzi, Carlo, Appendino, Lucia, Arena, Sebastiano, Baione, Viola, Balgera, Roberto, Barcella, Valeria, Baroncini, Damiano, Barrilà, Caterina, Bellacosa, Alessandra, Bellucci, Gianmarco, Bergamaschi, Roberto, Bergamaschi, Valeria, Bezzini, Daiana, Biolzi, Beatrice, Bisecco, Alvino, Bonavita, Simona, Borriello, Giovanna, Bosa, Chiara, Bosco, Antonio, Bovis, Francesca, Bozzali, Marco, Brambilla, Laura, Buccafusca, Maria, Bucciantini, Elisabetta, Bucello, Sebastiano, Buscarinu, Maria Chiara, Cabboi, Maria Paola, Calabrese, Massimiliano, Calabria, Francesca, Caleri, Francesca, Camilli, Federico, Caniatti, Luisa Maria, Cantello, Roberto, Capra, Ruggero, Capuano, Rocco, Carta, Patrizia, Celani, Maria Grazia, Cellerino, Maria, Cerqua, Raffaella, Chisari, Clara, Clerici, Raffaella, Clerico, Marinella, Cola, Gaia, Conte, Antonella, Conti, Marta Zaffira, Cordano, Christian, Cordera, Susanna, Corea, Francesco, Correale, Claudio, Cottone, Salvatore, Crescenzo, Francesco, Curti, Erica, dʼAmbrosio, Alessandro, DʼAmico, Emanuele, Danni, Maura Chiara, dʼArma, Alessia, Dattola, Vincenzo, de Biase, Stefano, Luca, Giovanna De, Mercanti, Stefania Federica De, De Mitri, Paolo, De Stefano, Nicola, Cava, Marco Della, Napoli, Mario di, Sapio, Alessia Di, Docimo, Renato, Dutto, Anna, Evangelista, Luana, Fanara, Salvatore, Diana, Ferraro, Ferrò, Maria Teresa, Fioretti, Cristina, Fratta, Mario, Frau, Jessica, Fronza, Marzia, Furlan, Roberto, Gajofatto, Alberto, Gallo, Antonio, Gallo, Paolo, Gasperini, Claudio, Ghazaryan, Anna, Giometto, Bruno, Gobbin, Francesca, Govone, Flora, Granella, Franco, Grange, Erica, Grasso, Maria Grazia, Guareschi, Angelica, Guaschino, Clara, Guerrieri, Simone, Guidetti, Donata, Iaffaldano, Pietro, Ianniello, Antonio, Iasevoli, Luigi, Imperiale, Daniele, Infante, Maria Teresa, Iodice, Rosa, Iovino, Aniello, Konrad, Giovanna, Landi, Doriana, Lanzillo, Roberta, Lapucci, Caterina, Lavorgna, Luigi, LʼEpiscopo, Maria Rita, Leva, Serena, Liberatore, Giuseppe, Lo Re, Marianna, Longoni, Marco, Lopiano, Leonardo, Lorefice, Lorena, Lucchini, Matteo, Lus, Giacomo, Maimone, Davide, Malentacchi, Maria, Mallucci, Giulia, Malucchi, Simona, Mancinelli, Chiara Rosa, Mancinelli, Luca, Manganotti, Paolo, Maniscalco, Giorgia Teresa, Mantero, Vittorio, Marangoni, Sabrina, Marastoni, Damiano, Marinelli, Fabiana, Marti, Alessandro, Boneschi, Filippo Martinelli, Masserano Zoli, Federco, Matta, Francesca, Mendozzi, Laura, Meucci, Giuseppe, Miante, Silvia, Miele, Giuseppina, Milano, Eva, Mirabella, Massimiliano, Missione, Rosanna, Moccia, Marcello, Moiola, Lucia, Montepietra, Sara, MontiBragadin, Margherita, Montini, Federico, Motta, Roberta, Nardone, Raffaele, Nicoletti, Carolina Gabri, Nobile-Orazio, Eduardo, Nozzolillo, Agostino, Onofrj, Marco, Orlandi, Riccardo, Palmieri, Anna, Paolicelli, Damiano, Pasquali, Livia, Pastò, Luisa, Pedrazzoli, Elisabetta, Petracca, Maria, Petrone, Alfredo, Piantadosi, Carlo, Pietroboni, Anna M, Pinardi, Federica, Ponzano, Marta, Portaccio, Emilio, Pozzato, Mattia, Pozzilli, Carlo, Prosperini, Luca, Protti, Alessandra, Ragonese, Paolo, Rasia, Sarah, Realmuto, Sabrina, Repice, Anna, Rigoni, Eleonora, Rilla, Maria Teresa, Rinaldi, Francesca, Romano, Calogero Marcello, Ronzoni, Marco, Rovaris, Marco, Ruscica, Francesca, Sabattini, Loredana, Salemi, Giuseppe, Saraceno, Lorenzo, Sartori, Alessia, Sartori, Arianna, Sbragia, Elvira, Scarano, Giuditta Ilaria, Scarano, Valentina, Schillaci, Valentina, Sessa, Maria, Sgarito, Caterina, Sibilia, Grazia, Siciliano, Gabriele, Signori, Alessio, Signoriello, Elisabetta, Sinisi, Leonardo, Sireci, Francesca, Sola, Patrizia, Solaro, Claudio, Sotgiu, Stefano, Sparaco, Maddalena, Stromillo, Maria Laura, Strumia, Silvia, Susani, Emanuela Laura, Tabiadon, Giulietta, Teatini, Francesco, Tomassini, Valentina, Tonietti, Simone, Torri, Clerici Valentina, Tortorella, Carla, Toscano, Simona, Totaro, Rocco, Trotta, Maria, Turano, Gabriella, Ulivelli, Monica, Valentino, Manzo, Vaula, Giovanna, Vecchio, Domizia, Vercellino, Marco, Verrengia, Elena Pinuccia, Vianello, Marika, Virgilio, Eleonora, Vitetta, Francesca, Vollaro, Stefano, Zaffaroni, Mauro, Zampolini, Mauro, Zarbo, Ignazio Roberto, and Zuliani, Luigi

Published
2022
Full Text
View/download PDF

17. Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Author

Boffa, Giacomo, Massacesi, Luca, Inglese, Matilde, Mariottini, Alice, Capobianco, Marco, Lucia, Moiola, Amato, Maria Pia, Cottone, Salvatore, Gualandi, Francesca, De Gobbi, Marco, Greco, Raffaella, Scimè, Rosanna, Frau, Jessica, Zimatore, Giovanni Bosco, Bertolotto, Antonio, Comi, Giancarlo, Uccelli, Antonio, Signori, Alessio, Angelucci, Emanuele, Innocenti, Chiara, Ciceri, Fabio, Repice, Anna Maria, Sormani, Maria Pia, Saccardi, Riccardo, and Mancardi, Gianluigi

Published
2021
Full Text
View/download PDF

27. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Published
2020
Full Text
View/download PDF

34. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band

Author

Ferraro, Diana, Franciotta, Diego, Bedin, Roberta, Solaro, Claudio, Cocco, Eleonora, Santangelo, Mario, Immovilli, Paolo, Gajofatto, Alberto, Calabrese, Massimiliano, Di Filippo, Massimiliano, Orlandi, Riccardo, Simone, Anna Maria, Vitetta, Francesca, Capello, Elisabetta, Giunti, Debora, Murialdo, Alessandra, Frau, Jessica, Mariotto, Sara, Gallina, Antongiulio, Gasperini, Claudio, Sola, Patrizia, and On behalf of the RIREMS group (Rising Italian Researchers in Multiple Sclerosis)

Published
2017
Full Text
View/download PDF

38. Antibody response elicited by the SARS‐CoV‐2 vaccine booster in patients with multiple sclerosis: Who gains from it?

Author

Schiavetti, Irene, Inglese, Matilde, Frau, Jessica, Signoriello, Elisabetta, Caleri, Francesca, Stromillo, Maria Laura, Ferrò, Maria Teresa, Rilla, Maria Teresa, Gandoglia, Ilaria, Gazzola, Paola, Brichetto, Giampaolo, Pasquali, Livia, Grimaldi, Luigi, Ulivelli, Monica, Marinelli, Fabiana, Cordera, Susanna, Clerico, Marinella, Conte, Antonella, Salvetti, Marco, and Battaglia, Mario Alberto

Subjects
COVID-19 vaccines, BOOSTER vaccines, ANTIBODY formation, MULTIPLE sclerosis, IMMUNOSUPPRESSIVE agents
Abstract

Background and purpose: Although two doses of COVID‐19 vaccine elicited a protective humoral response in most persons with multiple sclerosis (pwMS), a significant group of them treated with immunosuppressive disease‐modifying therapies (DMTs) showed less efficient responses. Methods: This prospective multicenter observational study evaluates differences in immune response after a third vaccine dose in pwMS. Results: Four hundred seventy‐three pwMS were analyzed. Compared to untreated patients, there was a 50‐fold decrease (95% confidence interval [CI] = 14.3–100.0, p < 0.001) in serum SARS‐CoV‐2 antibody levels in those on rituximab, a 20‐fold decrease (95% CI = 8.3–50.0, p < 0.001) in those on ocrelizumab, and a 2.3‐fold decrease (95% CI = 1.2–4.6, p = 0.015) in those on fingolimod. As compared to the antibody levels after the second vaccine dose, patients on the anti‐CD20 drugs rituximab and ocrelizumab showed a 2.3‐fold lower gain (95% CI = 1.4–3.8, p = 0.001), whereas those on fingolimod showed a 1.7‐fold higher gain (95% CI = 1.1–2.7, p = 0.012), compared to patients treated with other DMTs. Conclusions: All pwMS increased their serum SARS‐CoV‐2 antibody levels after the third vaccine dose. The mean antibody values of patients treated with ocrelizumab/rituximab remained well below the empirical "protective threshold" for risk of infection identified in the CovaXiMS study (>659 binding antibody units/mL), whereas for patients treated with fingolimod this value was significantly closer to the cutoff. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study

Author

Idda, Maria Laura, primary, Pitzalis, Maristella, additional, Lodde, Valeria, additional, Loizedda, Annalisa, additional, Frau, Jessica, additional, Lobina, Monia, additional, Zoledziewska, Magdalena, additional, Virdis, Francesca, additional, Delogu, Giuseppe, additional, Marini, Maria Giuseppina, additional, Mingoia, Maura, additional, Masala, Marco, additional, Lorefice, Lorena, additional, Fronza, Marzia, additional, Carmagnini, Daniele, additional, Carta, Elisa, additional, Pilotto, Silvy, additional, Castiglia, Paolo, additional, Chessa, Paola, additional, Uzzau, Sergio, additional, Farina, Gabriele, additional, Solla, Paolo, additional, Steri, Maristella, additional, Devoto, Marcella, additional, Fiorillo, Edoardo, additional, Floris, Matteo, additional, Zarbo, Roberto Ignazio, additional, Cocco, Eleonora, additional, and Cucca, Francesco, additional

Published
2022
Full Text
View/download PDF

42. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

Author

Sormani, Maria Pia, primary, Schiavetti, Irene, additional, Inglese, Matilde, additional, Carmisciano, Luca, additional, Laroni, Alice, additional, Lapucci, Caterina, additional, Visconti, Valeria, additional, Serrati, Carlo, additional, Gandoglia, Ilaria, additional, Tassinari, Tiziana, additional, Perego, Germana, additional, Brichetto, Giampaolo, additional, Gazzola, Paola, additional, Mannironi, Antonio, additional, Stromillo, Maria Laura, additional, Cordioli, Cinzia, additional, Landi, Doriana, additional, Clerico, Marinella, additional, Signoriello, Elisabetta, additional, Cocco, Eleonora, additional, Frau, Jessica, additional, Ferrò, Maria Teresa, additional, Di Sapio, Alessia, additional, Pasquali, Livia, additional, Ulivelli, Monica, additional, Marinelli, Fabiana, additional, Pizzorno, Matteo, additional, Callari, Graziella, additional, Iodice, Rosa, additional, Liberatore, Giuseppe, additional, Caleri, Francesca, additional, Repice, Anna Maria, additional, Cordera, Susanna, additional, Battaglia, Mario Alberto, additional, Salvetti, Marco, additional, Franciotta, Diego, additional, Uccelli, Antonio, additional, Maglione, Alessandro, additional, Sapio, Alessia Di, additional, Signori, Alessio, additional, Iovino, Aniello, additional, Maria Repice, Anna, additional, Gabri Nicoletti, Carolina, additional, Mancinelli, Chiara Rosa, additional, Bezzini, Daiana, additional, Carmagnini, Daniele, additional, Brogi, Davide, additional, Nobile Orazio, Eduardo, additional, Nako, Enri, additional, Assandrir, Ester, additional, Baldi, Federica, additional, Ansaldi, Filippo, additional, Bovis, Francesca, additional, Siciliano, Gabriele, additional, Cola, Gaia, additional, Lus, Giacomo, additional, Icardi, Giancarlo, additional, Bellucci, Gianmarco, additional, Da Rin, Giorgio, additional, Alessandra Marfia, Girolama, additional, Vazzoler, Giulia, additional, Trivelli, Giuseppe, additional, Maietta, Ilaria, additional, Sticchi, Laura, additional, Lorefice, Lorena, additional, Ruggiero, Lucia, additional, Manzino, Marcello, additional, Monti Bragadin, Margherita, additional, Chiara Buscarinu, Maria, additional, Gagliardi, Maria, additional, Laura Stromillo, Maria, additional, Pia Sormani, Maria, additional, Rilla, Maria Teresa, additional, Alberto Battaglia, Mario, additional, Ponzano, Marta, additional, Fronza, Marzia, additional, Del Sette, Massimo, additional, Scialabba, Matteo, additional, Bedognetti, Michele, additional, De Rossi, Nicola, additional, De Stefano, Nicola, additional, Bigi, Rachele, additional, Dubbioso, Raffaele, additional, Reniè, Roberta, additional, Fabbri, Sabrina, additional, Rasia, Sarah, additional, Rolla, Simona, additional, Platzgummer, Stefan, additional, and Carlini, Valentina, additional

Published
2022
Full Text
View/download PDF

43. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

Author

Laroni, Alice, Signori, Alessio, Maniscalco, Giorgia T., Lanzillo, Roberta, Russo, Cinzia Valeria, Binello, Eleonora, Lo Fermo, Salvatore, Repice, Annamaria, Annovazzi, Pietro, Bonavita, Simona, Clerico, Marinella, Baroncini, Damiano, Prosperini, Luca, La Gioia, Sara, Rossi, Silvia, Cocco, Eleonora, Frau, Jessica, Torri Clerici, Valentina, Signoriello, Elisabetta, Sartori, Arianna, Zarbo, Ignazio Roberto, Rasia, Sarah, Cordioli, Cinzia, Cerqua, Raffaella, Di Sapio, Alessia, Lavorgna, Luigi, Pontecorvo, Simona, Barrilà, Caterina, Saccà, Francesco, Frigeni, Barbara, Esposito, Sabrina, Ippolito, Domenico, Gallo, Fabio, and Sormani, Maria Pia

Published
2017
Full Text
View/download PDF

46. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

Author

Boffa, Giacomo, Signori, Alessio, Massacesi, Luca, Mariottini, Alice, Sbragia, Elvira, Cottone, Salvatore, Amato, Maria Pia, Gasperini, Claudio, Moiola, Lucia, Meletti, Stefano, Repice, Anna Maria, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Filippi, Massimo, De Luca, Giovanna, Lus, Giacomo, Zaffaroni, Mauro, Sola, Patrizia, Conte, Antonella, Nistri, Riccardo, Aguglia, Umberto, Granella, Franco, Galgani, Simonetta, Caniatti, Luisa Maria, Lugaresi, Alessandra, Romano, Silvia, Iaffaldano, Pietro, Cocco, Eleonora, Saccardi, Riccardo, Angelucci, Emanuele, Trojano, Maria, Mancardi, Giovanni Luigi, Sormani, Maria Pia, Inglese, Matilde, Capobianco, Marco, Zimatore, Giovanni Bosco, Frau, Jessica, Scarpini, Elio, Meucci, Giuseppe, Guidetti, Donata, Gualandi, Francesca, Varaldo, Riccardo, Raiola, Anna Maria, Innocenti, Chiara, Zoli, Valerio, Ciceri, Fabio, Greco, Raffaella, Scim`e, Rosanna, De Gobbi, Marco, Barilaro, Alessandro, Boffa, Giacomo, Signori, Alessio, Massacesi, Luca, Mariottini, Alice, Sbragia, Elvira, Cottone, Salvatore, Amato, Maria Pia, Gasperini, Claudio, Moiola, Lucia, Meletti, Stefano, Repice, Anna Maria, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Filippi, Massimo, De Luca, Giovanna, Lus, Giacomo, Zaffaroni, Mauro, Sola, Patrizia, Conte, Antonella, Nistri, Riccardo, Aguglia, Umberto, Granella, Franco, Galgani, Simonetta, Caniatti, Luisa Maria, Lugaresi, Alessandra, Romano, Silvia, Iaffaldano, Pietro, Cocco, Eleonora, Saccardi, Riccardo, Angelucci, Emanuele, Trojano, Maria, Mancardi, Giovanni Luigi, Sormani, Maria Pia, and Inglese, Matilde

Subjects
Hematopoietic Stem Cell Transplantation, Active Secondary Progressive Multiple Sclerosis, Neurology (clinical), Research Article
Abstract

Background and ObjectivesUncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study, we compared the effect of AHSCT with that of other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active SPMS.MethodsWe collected data from the Italian Bone Marrow Transplantation Study Group and the Italian Multiple Sclerosis Register. Patients were considered eligible if treatment had been started after the diagnosis of SPMS. Disability worsening was assessed by the cumulative proportion of patients with a 6-month confirmed disability progression (CDP) according to the Expanded Disability Status Scale (EDSS) score. Key secondary endpoints were the EDSS time trend after treatment start and the prevalence of disability improvement over time. Time to first CDP was assessed by means of proportional hazard Cox regression models. A linear mixed model with a time × treatment group interaction was used to assess the longitudinal EDSS time trends. Prevalence of improvement was estimated using a modified Kaplan-Meier estimator and compared between groups by bootstrapping the area under the curve.ResultsSeventy-nine AHSCT-treated patients and 1975 patients treated with other DMTs (beta interferons, azathioprine, glatiramer-acetate, mitoxantrone, fingolimod, natalizumab, methotrexate, teriflunomide, cyclophosphamide, dimethyl fumarate, and alemtuzumab) were matched to reduce treatment selection bias using propensity score and overlap weighting approaches. Time to first CDP was significantly longer in transplanted patients (hazard ratio [HR] = 0.50; 95% CI = 0.31–0.81;p= 0.005), with 61.7% of transplanted patients free from CPD at 5 years. Accordingly, EDSS time trend over 10 years was higher in patients treated with other DMTs than in AHSCT-treated patients (+0.157 EDSS points per year compared with −0.013 EDSS points per year; interactionp< 0.001). Patients who underwent AHSCT were more likely to experience a sustained disability improvement: 34.7% of patients maintained an improvement (a lower EDSS than baseline) 3 years after transplant vs 4.6% of patients treated by other DMTs (p< 0.001).DiscussionThe use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy.Classification of EvidenceThis study provides Class III evidence that autologous hematopoietic stem cell transplants prolonged the time to CDP compared with other DMTs.

Published
2022

49. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients

Author

Pitzalis, Maristella, primary, Idda, Maria Laura, additional, Lodde, Valeria, additional, Loizedda, Annalisa, additional, Lobina, Monia, additional, Zoledziewska, Magdalena, additional, Virdis, Francesca, additional, Delogu, Giuseppe, additional, Pirinu, Federica, additional, Marini, Maria Giuseppina, additional, Mingoia, Maura, additional, Frau, Jessica, additional, Lorefice, Lorena, additional, Fronza, Marzia, additional, Carmagnini, Daniele, additional, Carta, Elisa, additional, Orrù, Valeria, additional, Uzzau, Sergio, additional, Solla, Paolo, additional, Loi, Federica, additional, Devoto, Marcella, additional, Steri, Maristella, additional, Fiorillo, Edoardo, additional, Floris, Matteo, additional, Zarbo, Ignazio Roberto, additional, Cocco, Eleonora, additional, and Cucca, Francesco, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results